ViewRay Announces Participation in the B. Riley Oncology Investor Conference

Rhea-AI Summary

ViewRay, Inc. (NASDAQ: VRAY) announced its participation in the B. Riley Oncology Investor Conference scheduled for January 20, 2021. Management will engage in a fireside chat and will hold one-on-one meetings with investors. An audio recording of the chat will be accessible for seven days post-event on the company’s investor website. ViewRay is known for its MRIdian® radiation therapy system, featuring advanced MR imaging specifically designed for radiation oncology to overcome challenges like beam distortion and skin toxicity.

Positive

• Participation in B. Riley Oncology Investor Conference could enhance investor visibility.
• 1x1 meetings with investors may attract potential investment opportunities.

Negative

• None.

CLEVELAND, Jan. 15, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) (the "Company") today announced that members of management will be participating in a fireside chat at the B. Riley Oncology Investor Conference on Wednesday, January 20, 2021. ViewRay will also be hosting 1x1 meetings with investors.

An audio recording of the fireside chat will be available after the event on the "Financial Events and Webinars" portion of ViewRay's investor website at https://investors.viewray.com/events-and-presentations/upcoming-events. The recording will be available for 7 days after the date of the presentation.

About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

View original content:http://www.prnewswire.com/news-releases/viewray-announces-participation-in-the-b-riley-oncology-investor-conference-301209021.html

SOURCE ViewRay, Inc.

FAQ

What event is ViewRay participating in on January 20, 2021?

ViewRay is participating in the B. Riley Oncology Investor Conference.

What is VRAY's main product?

VRAY's main product is the MRIdian® radiation therapy system.

Where can I find the audio recording of ViewRay's fireside chat?

The audio recording will be available on ViewRay's investor website for seven days after the event.

What is significant about the MRIdian system offered by ViewRay?

The MRIdian system is designed to address specific challenges in radiation oncology, including beam distortion and skin toxicity.